Policy & Regulation
Shanghai Medicilon enters strategic collaboration agreement with and Jiangsu Hengrui Pharmaceuticals
1 August 2024 -

China-based company engaged in pre-clinical comprehensive research and development services of biomedicine Shanghai Medicilon Inc. announced on Wednesday that it has entered into a strategic collaboration agreement with Jiangsu Hengrui Pharmaceuticals Co., Ltd., a China-based pharmaceutical company.

The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs, small nucleic acids, and CGT (cell and gene therapy) drugs. The goal of this partnership is to advance the innovation of the Chinese pharmaceutical industry to compete on an international level.

The companies plan to integrate Medicilon's preclinical R&D expertise with Hengrui Pharma's innovative strategies and market influence. Medicilon will leverage its technological advantages in drug discovery and development to provide Hengrui Pharma with a range of preclinical services, focusing on efficacy testing, pharmacokinetics, and toxicology studies for new drug modalities. Medicilon and Hengrui Pharma will combine efforts to generate breakthroughs in pharmaceutical therapies.

Hengrui Pharma's vice general manager & global R&D president Lianshan Zhang, said, 'Medicilon possesses robust innovation capabilities and service quality in this field, making it a trusted CRO partner. The collaboration between Hengrui Pharma and Medicilon not only acknowledges past achievements but also represents a deep exploration of future collaboration potential and forward-looking strategic planning.'

Login
Username:

Password: